01
Orthobiology · Lund, Sweden
Moroxite AB
Synthetic bone replacement for spinal fusion. FDA Breakthrough Device Designation. Led by the founding team behind the Bonesupport exit.
Webinar · Co-hosted by Peter Moeller and the Moroxite CEO · 40 seats.
02
Munich-Süd · Off-market
Position II · Residential
A 90-unit residential block in a high-demographic-tailwind sub-market. Acquired below replacement cost. Co-invest open to qualified family offices.
By Invitation
03
DACH · Series A
Position III · B2B SaaS
European supply-chain optimization platform. Founders from a previously-acquired listed peer. Round closing imminent.
Reserved